About Biogen Pharmachem Industries Limited
Data last updated:
Biogen Pharmachem Industries Limited is a public limited company based in Rajkot, Gujarat, India. It operates in the brokerage and trading services segment of the financial services sector. It was incorporated on 13 July 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L51100GJ1995PLC026702. It is a listed company as per MCA records. Its shares are listed on BSE: 531752.
The company has an authorised share capital of ₹108 Cr and a paid-up capital of ₹105.3 Cr. It was formerly known as Wellworth Overseas Limited and Sun Techno Overseas Limited. It is led by directors including Kelash Bunkar (Whole-Time Director) and Chandrakant Govindbhai Parmar.
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Shop No 8 First Floor Makers – 1 Building Jawahar Road, Rajkot, Gujarat, India – 360001.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹2.55 Cr, a growth of 112.5% compared to the previous year. For the same year it recorded a net profit of ₹86 Lakh (net margin 33.7%) and EBITDA of ₹95 Lakh (EBITDA margin 37.3%). The net worth stands at ₹99.09 Cr (up 7.8% YoY). Total assets are valued at ₹99.09 Cr (up 7.8% YoY).
Court records list 3 cases involving the company, including 2 filed by the company and 1 filed against it. The company has 138 deals on record (138 market trades); the latest was in May 2026.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website suntechnooverseas.tk.
Company details
Name history
Biogen Pharmachem Industries has undergone 2 name changes throughout its history. The company was previously known as Wellworth Overseas Limited, and Sun Techno Overseas Limited. The current legal name is Biogen Pharmachem Industries Limited.
| Company Name | Status |
|---|---|
| Biogen Pharmachem Industries Limited | Current |
| Wellworth Overseas Limited | Previous |
| Sun Techno Overseas Limited | Previous |
CIN history
Biogen Pharmachem Industries has one previous CIN (Corporate Identification Number): L65910GJ1995PLC026702. The current CIN is L51100GJ1995PLC026702, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51100GJ1995PLC026702 | Current |
| L65910GJ1995PLC026702 | Previous |
Contact details
Biogen Pharmachem Industries Limited's registered office is in Rajkot, Gujarat. Its website is suntechnooverseas.tk. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Apps
- Registered AddressShop No 8 First Floor Makers – 1 Building Jawahar Road, Rajkot, Gujarat, India – 360001
- IndustryFinancial Services, Brokerage & Trading Services
To see the full contact details of Biogen Pharmachem Industries Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Biogen Pharmachem Industries Limited
FY 2025-26 filings availableBiogen Pharmachem Industries Limited reported revenue of ₹2.55 Cr (up 112.5% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2.55 | 1.20 | 2.38 | 0.00 | 2.47 | 1.62 | 0.00 |
| Revenue growth | +112.5% | -49.6% | - | -100.0% | +52.5% | - | - |
| EBITDA | 0.95 | (0.29) | 1.93 | (0.45) | (0.01) | (1.60) | (0.12) |
| EBITDA margin | +37.3% | -24.2% | +81.1% | - | -0.4% | -98.8% | - |
| Profit before tax | 0.96 | (0.29) | 1.93 | 0.46 | 0.00 | (1.60) | (0.12) |
| Net profit | 0.86 | (0.29) | 1.93 | (0.20) | 0.00 | (1.60) | (0.12) |
| Net profit margin | +33.7% | -24.2% | +81.1% | - | 0.0% | -98.8% | - |
| EPS (₹) | 0.01 | 0.00 | 0.03 | 0.01 | 0.00 | (0.02) | 0.00 |
| Balance sheet | |||||||
| Total assets | 99.09 | 91.93 | 56.52 | 54.59 | 54.13 | 54.14 | 56.05 |
| Net worth | 99.09 | 91.93 | 56.52 | 54.59 | 54.13 | 54.14 | 55.75 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 |
| Cash & bank | 0.32 | 2.02 | 0.02 | 0.13 | 0.08 | 0.01 | 0.00 |
| Net working capital | 0.18 | 2.58 | (0.20) | (0.08) | 1.11 | 2.45 | 8.00 |
| Cash flow | |||||||
| Cash from operations | 1.57 | (1.08) | 1.94 | 1.70 | 1.40 | 3.95 | (1.21) |
| Cash from investing | (9.56) | (32.62) | (2.06) | (1.66) | (1.32) | (3.64) | 1.54 |
| Cash from financing | 6.30 | 35.70 | 0.00 | 0.00 | 0.00 | (0.31) | (0.32) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.44 | 0.58 | 0.54 | 0.00 | 0.00 | 1.35 | 0.00 | 0.00 |
| Revenue growth (YoY) | - | -57.0% | - | - | +100.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | (0.10) | 1.54 | 0.00 | 0.23 | (0.65) |
| Total expenses | 0.22 | 0.94 | 0.08 | 0.39 | 0.20 | 0.17 | 0.54 | 0.35 |
| EBITDA | 0.22 | (0.36) | 0.46 | (0.39) | (0.20) | 1.18 | (0.54) | (0.35) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.22 | (0.36) | 0.46 | (0.49) | 1.34 | 1.18 | (0.31) | (1.00) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.44 | 0.58 | 0.54 | 0.00 | 0.00 | 1.35 | 0.00 | 0.00 |
| Revenue growth (YoY) | - | -57.0% | - | - | +100.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | (0.10) | 1.54 | 0.00 | 0.23 | (0.65) |
| Total expenses | 0.22 | 0.94 | 0.08 | 0.39 | 0.20 | 0.17 | 0.54 | 0.35 |
| EBITDA | 0.22 | (0.36) | 0.46 | (0.39) | (0.20) | 1.18 | (0.54) | (0.35) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.22 | (0.36) | 0.46 | (0.49) | 1.34 | 1.18 | (0.31) | (1.00) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.55 | 1.20 | 2.38 | 0.00 | 2.47 | 1.62 | 0.00 |
| Revenue growth | +112.5% | -49.6% | - | -100.0% | +52.5% | - | - |
| Other income | 0.01 | 0.00 | 0.00 | 0.91 | 0.01 | 0.00 | 0.00 |
| Total expenses | 1.60 | 1.49 | 0.45 | 0.45 | 2.48 | 3.22 | 0.12 |
| Employee cost | 0.28 | 0.17 | 0.08 | 0.17 | 0.05 | 0.01 | 0.04 |
| EBITDA | 0.95 | (0.29) | 1.93 | (0.45) | (0.01) | (1.60) | (0.12) |
| EBITDA margin | +37.3% | -24.2% | +81.1% | - | -0.4% | -98.8% | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.96 | (0.29) | 1.93 | 0.46 | 0.00 | (1.60) | (0.12) |
| Tax | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.86 | (0.29) | 1.93 | (0.20) | 0.00 | (1.60) | (0.12) |
| Net profit margin | +33.7% | -24.2% | +81.1% | - | 0.0% | -98.8% | - |
| EPS (₹) | 0.01 | 0.00 | 0.03 | 0.01 | 0.00 | (0.02) | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 90.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 |
| Reserves & surplus | 8.83 | (9.03) | (8.74) | (10.67) | (11.13) | (11.12) | (9.51) |
| Shareholders' funds (net worth) | 99.09 | 91.93 | 56.52 | 54.59 | 54.13 | 54.14 | 55.75 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 |
| Total liabilities | - | - | 56.52 | 54.59 | 54.13 | 54.14 | 56.05 |
| Assets | |||||||
| Gross block | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net block | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 32.78 | 23.84 | 5.44 | 8.85 | 6.95 | 9.49 | 6.45 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54 | 8.03 |
| Cash & bank balances | 0.32 | 2.02 | 0.02 | 0.13 | 0.08 | 0.01 | 0.00 |
| Loans & advances | 0.17 | 0.65 | 0.08 | 0.03 | 1.85 | 0.01 | 0.01 |
| Total current assets | 0.49 | 2.67 | 0.10 | 0.16 | 1.93 | 2.56 | 8.04 |
| Total current liabilities | 0.31 | 0.09 | 0.30 | 0.24 | 0.82 | 0.11 | 0.04 |
| Net working capital | 0.18 | 2.58 | (0.20) | (0.08) | 1.11 | 2.45 | 8.00 |
| Total assets | 99.09 | 91.93 | 56.52 | 54.59 | 54.13 | 54.14 | 56.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.02 | 0.02 | 0.13 | 0.08 | 0.01 | 0.00 | 0.00 |
| Net cash from operating activities | 1.57 | (1.08) | 1.94 | 1.70 | 1.40 | 3.95 | (1.21) |
| Net cash from investing activities | (9.56) | (32.62) | (2.06) | (1.66) | (1.32) | (3.64) | 1.54 |
| Net cash from financing activities | 6.30 | 35.70 | 0.00 | 0.00 | 0.00 | (0.31) | (0.32) |
| Net change in cash | (1.69) | 2.00 | (0.11) | 0.05 | 0.08 | 0.00 | 0.00 |
| Closing cash | 0.32 | 2.02 | 0.02 | 0.13 | 0.08 | 0.01 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +112.5% | -49.6% | - | -100.0% | +52.5% | - | - |
| EBITDA growth | +427.6% | -115.0% | +528.9% | -4400.0% | +99.4% | -1233.3% | - |
| PBT growth | +9998.0% | - | +319.6% | +9997.0% | +9997.0% | -1233.3% | -1100.0% |
| Net income growth | +396.6% | -115.0% | +1065.0% | - | +100.0% | -1233.3% | - |
| Revenue CAGR (3Y) | - | -21.4% | +13.7% | - | +37.5% | +145.1% | - |
| EBITDA CAGR (3Y) | - | +207.2% | - | +55.4% | 0.0% | -37.7% | -2.6% |
| Profitability & leverage | |||||||
| Net income margin | +33.7% | -24.2% | +81.1% | - | 0.0% | -98.8% | - |
| Return on capital employed | +1.0% | 0.0% | +3.0% | -0.3% | 0.0% | 0.0% | 0.0% |
| Return on net worth | +0.9% | 0.0% | +3.0% | -0.3% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 0.00 | 0.00 | 0.00 | 0.00 | 1.95 | 0.31 | 0.00 |
| EPS (₹) | 0.01 | 0.00 | 0.03 | 0.01 | 0.00 | (0.02) | 0.00 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 1.10 | 0.86 | 0.87 | 0.84 | 0.83 | 0.83 | 0.85 |
To see the full year-wise statements and ratios of Biogen Pharmachem Industries Limited, buy the company report.
Board of directors of Biogen Pharmachem Industries Limited
Biogen Pharmachem Industries has 6 current directors and 31 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chandrakant Govindbhai Parmar Also directs: Malabar Trading Company Limited | Director | 22 Nov 2021 | 4 Years 11 Months | Current |
| Harshadkumar Chhanabhai Rathod Also directs: Shree Ganesh Bio-Tech (India) Limited | Director | 22 Mar 2023 | 3 Years 7 Months | Current |
| Narendrakumar Ashokbhai Vaniya Also directs: Saianand Commercial Limited, Suncare Traders Limited | Director | 22 Mar 2023 | 3 Years 7 Months | Current |
| Aman Pravinkumar Patel Also directs: Regis Industries Limited, Shree Ganesh Bio-Tech (India) Limited | Director | 05 Feb 2025 | 1 Years 8 Months | Current |
| Kelash Bunkar Also directs: Regis Industries Limited, Amerise Biosciences Limited | Whole-Time Director | 05 Feb 2025 | 1 Years 8 Months | Current |
| Chhayaben Maheshbhai Parmar Also directs: Regis Industries Limited, Suncare Traders Limited | Director | 09 Jan 2024 | 2 Years 9 Months | Current |
Auditor
Biogen Pharmachem Industries Limited is audited by RISHI SEKHRI A N D ASSOCIATES, for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| RISHI SEKHRI A N D ASSOCIATES, | FY 2023 | 128216W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 0.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 100.00%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 100.00% | 100.00% | 100.00% | 100.00% |
Deals & funding
Biogen Pharmachem Industries Limited has 138 deals on record (138 market trades); the latest was in May 2026.
Deals on record (5 of 138)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2024 | Market trade | ₹43.6 Lakh | Seller: Topgain Finance Private Limited |
| Jul 2024 | Market trade | ₹63.9 Lakh | Buyer: Topgain Finance Private Limited Seller: Topgain Finance Private Limited |
| Jul 2024 | Market trade | ₹93 Lakh | Buyer: Topgain Finance Private Limited , Sahastraa Advisors Private Limited Seller: Topgain Finance Private Limited , Sahastraa Advisors Private Limited |
| Jan 2024 | Market trade | ₹46.8 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited Seller: Multiplier Share and Stock Advisors Private Limited |
| Dec 2023 | Market trade | ₹1.27 Cr | Buyer: Multiplier Share and Stock Advisors Private Limited |
To see the full deal history of Biogen Pharmachem Industries Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Biogen Pharmachem Industries Limited has 3 court cases on record: 2 filed by Biogen Pharmachem Industries, 1 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 0 | 0 |
| High courts | 1 | 1 | 0 |
| Supreme Court | 1 | 0 | 0 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Gujarat | Court case (AO) | Filed against the company by M/S Suzlon-Wind Farm Service Ltd. | Disposed |
| Supreme Court | Court case (Special Leave Petition (Civil)) | Filed by the company against M/S Suzlon Wind Farm Services Limited | Disposed |
| District court, Ahmedabad, Gujarat | Court case (CS CCC) | Filed by the company against Suzlon Wind Farm Services Ltd. | Disposed |
To see the full case history of Biogen Pharmachem Industries Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Biogen Pharmachem Industries Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Biogen Pharmachem Industries Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Biogen Pharmachem Industries Limited has 68 board changes on record since 1996: 37 appointments and 31 cessations. The latest: Aman Pravinkumar Patel was appointed as Director on 05 Feb 2025.
59 earlier events are in the company report.
News
Frequently asked questions
Biogen Pharmachem Industries is an active public limited company based in Rajkot, Gujarat, India. The company works in brokerage and trading services, within the financial services industry. It was incorporated on 13 July 1995 (31+ years old) and is registered under CIN L51100GJ1995PLC026702. Listed on BSE: 531752.
Biogen Pharmachem Industries reported revenue of ₹2.55 Cr for FY 2025-26 (up 112.5% YoY) based on standalone financials.
Biogen Pharmachem Industries has 6 current directors:
- Kelash Bunkar - Whole-Time Director
- Chandrakant Govindbhai Parmar - Director
- Harshadkumar Chhanabhai Rathod - Director
- Narendrakumar Ashokbhai Vaniya - Director
- Aman Pravinkumar Patel - Director
- Chhayaben Maheshbhai Parmar - Director
The latest financial statements of Biogen Pharmachem Industries on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Biogen Pharmachem Industries is L51100GJ1995PLC026702. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Biogen Pharmachem Industries is a listed company as per MCA records. Its shares are listed on BSE (code: 531752).
Biogen Pharmachem Industries has 3 court cases on record: 2 filed by the company and 1 filed against it. Most are in the district courts.
Biogen Pharmachem Industries was incorporated on 13 July 1995, making it 31+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Biogen Pharmachem Industries has 138 deals on record (138 market trades); the latest was in May 2026.
Aman Pravinkumar Patel was appointed as Director on 05 Feb 2025. Kelash Bunkar was appointed as Whole-Time Director on 05 Feb 2025. Komalben Nitinbhai Chauhan ceased to be Director on 05 Feb 2025. Biogen Pharmachem Industries has 68 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
